NASDAQ:CRSP

Crispr Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CRSP

*Your capital is at risk

$52.08

+0.0600 (+0.115%)

At Close: Jun 03, 2026

CRISPR Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -42.85. In total, the insiders bought 1.4M and sold 364.31K CRSP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-42.85
● Buy	1.4M shares
● Sell	364.31K shares
66% Buy Activity Moderate Positive Correlation
Sell Signal Medium Confidence Jan 22, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -42.85. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 18, 2026 Buy	Common Shares M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	13 250 Value: $709.1K
Jan 22, 2026 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	34 972 Value: $2.10M
Jan 22, 2026 Buy	Common Shares M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	34 972 Value: $1.58M
Jan 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	34 972 Value: $1.58M
Jan 22, 2026 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	60 000 Value: $3.61M
Jan 20, 2026 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	21 433 Value: $1.11M
Jan 20, 2026 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	8 567 Value: $446.3K
Jan 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	23 361 Value: $1.05M
Jan 06, 2026 Buy	Common Shares M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	6 339 Value: $280.9K
Jan 06, 2026 Buy	Common Shares M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	23 361 Value: $1.05M
Jan 06, 2026 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	18 933 Value: $1.14M
Jan 06, 2026 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	5 004 Value: $300.2K
Jan 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	6 339 Value: $280.9K
Jan 06, 2026 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	5 763 Value: $347.0K
Dec 22, 2025 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	3 528 Value: $194.4K
Dec 22, 2025 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	5 472 Value: $308.3K
Dec 22, 2025 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	1 000 Value: $56.9K
Dec 18, 2025 Sell	Common Shares G-Gift	Kulkarni Samarth Chief Executive Officer	CEO / President	30 000 Value: $0
Oct 17, 2025 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	50 895 Value: $3.46M
Oct 16, 2025 Buy	Common Shares M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	100 000 Value: $6.84M
Oct 16, 2025 Buy	Restricted Stock Units M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	100 000 Value: $6.84M
Oct 14, 2025 Sell	Common Shares S-Sale	Kasinger James R. General Counsel And Secretary	Officer	1 076 Value: $71.7K
Oct 14, 2025 Sell	Common Shares S-Sale	Kasinger James R. General Counsel And Secretary	Officer	1 076 Value: $71.7K
Oct 14, 2025 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	4 242 Value: $282.5K
Oct 14, 2025 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	4 242 Value: $282.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CRISPR THERAPEUTICS AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglo...

Read Full Profile Here